Key Points
- CEO insider sale: Pulmonx CEO Glendon French III sold 8,805 shares on Dec. 1 at an average price of $1.57 for $13,823.85, reducing his stake by 3.08% to 277,324 shares (valued ~ $435,399); the sale was disclosed in an SEC filing.
- Company remains unprofitable: Pulmonx reported ($0.34) EPS (beating estimates) but has a negative net margin of 61.9% and ROE of -77.6%, with revenue of $21.5M; the stock trades near $1.91 with a market cap of ~$78.6M and a 52-week range of $1.31–$9.37.
- Market view and ownership: Analysts hold a consensus "Hold" rating with an average target of $6.81, while institutional investors own about 91% of the stock and several funds (e.g., Citadel, Vestal Point) recently increased or initiated positions.
Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) CEO Glendon French III sold 8,805 shares of the firm's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $1.57, for a total value of $13,823.85. Following the completion of the transaction, the chief executive officer owned 277,324 shares in the company, valued at $435,398.68. The trade was a 3.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Pulmonx Price Performance
LUNG traded up $0.02 on Thursday, hitting $1.91. 74,055 shares of the company's stock were exchanged, compared to its average volume of 1,014,316. Pulmonx Corporation has a fifty-two week low of $1.31 and a fifty-two week high of $9.37. The stock has a market cap of $78.58 million, a price-to-earnings ratio of -1.35 and a beta of 0.22. The firm has a 50-day moving average price of $1.68 and a 200-day moving average price of $2.16. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62.
Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. Pulmonx had a negative net margin of 61.91% and a negative return on equity of 77.58%. The company had revenue of $21.50 million during the quarter, compared to analysts' expectations of $20.78 million. As a group, equities analysts anticipate that Pulmonx Corporation will post -1.55 earnings per share for the current year.
Institutional Trading of Pulmonx
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vestal Point Capital LP purchased a new stake in Pulmonx in the 3rd quarter valued at about $1,345,000. Susquehanna International Group LLP increased its position in shares of Pulmonx by 34.8% during the third quarter. Susquehanna International Group LLP now owns 67,794 shares of the company's stock valued at $110,000 after acquiring an additional 17,484 shares during the last quarter. Jain Global LLC acquired a new position in shares of Pulmonx in the 3rd quarter worth approximately $30,000. Citadel Advisors LLC boosted its position in shares of Pulmonx by 213.5% during the 3rd quarter. Citadel Advisors LLC now owns 217,176 shares of the company's stock worth $352,000 after purchasing an additional 147,904 shares during the period. Finally, Algert Global LLC boosted its position in shares of Pulmonx by 229.6% during the 3rd quarter. Algert Global LLC now owns 77,722 shares of the company's stock worth $126,000 after purchasing an additional 54,142 shares during the period. 91.04% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on LUNG shares. Lake Street Capital reduced their price objective on Pulmonx from $8.00 to $4.00 and set a "buy" rating on the stock in a research report on Tuesday, October 28th. Weiss Ratings reissued a "sell (e+)" rating on shares of Pulmonx in a research report on Wednesday, October 8th. D. Boral Capital reissued a "buy" rating and issued a $14.00 price objective on shares of Pulmonx in a report on Thursday, November 13th. Finally, Wall Street Zen upgraded shares of Pulmonx from a "sell" rating to a "hold" rating in a research report on Sunday, November 16th. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $6.81.
Check Out Our Latest Stock Analysis on LUNG
About Pulmonx
(
Get Free Report)
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
